Selecting the first chemical molecule inhibitor of HSP110 for colorectal cancer therapy.
Journal
Cell death and differentiation
ISSN: 1476-5403
Titre abrégé: Cell Death Differ
Pays: England
ID NLM: 9437445
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
25
10
2018
accepted:
12
04
2019
revised:
04
04
2019
pubmed:
10
5
2019
medline:
7
4
2021
entrez:
10
5
2019
Statut:
ppublish
Résumé
Pro-survival stress-inducible chaperone HSP110 is the only HSP for which a mutation has been found in a cancer. Multicenter clinical studies demonstrated a direct association between HSP110 inactivating mutation presence and excellent prognosis in colorectal cancer patients. Here, we have combined crystallographic studies on human HSP110 and in silico modeling to identify HSP110 inhibitors that could be used in colorectal cancer therapy. Two molecules (foldamers 33 and 52), binding to the same cleft of HSP110 nucleotide-binding domain, were selected from a chemical library (by co-immunoprecipitation, AlphaScreening, Interference-Biolayer, Duo-link). These molecules block HSP110 chaperone anti-aggregation activity and HSP110 association to its client protein STAT3, thereby inhibiting STAT3 phosphorylation and colorectal cancer cell growth. These effects were strongly decreased in HSP110 knockdown cells. Foldamer's 33 ability to inhibit tumor growth was confirmed in two colorectal cancer animal models. Although tumor cell death (apoptosis) was noted after treatment of the animals with foldamer 33, no apparent toxicity was observed, notably in epithelial cells from intestinal crypts. Taken together, we identified the first HSP110 inhibitor, a possible drug-candidate for colorectal cancer patients whose unfavorable outcome is associated to HSP110.
Identifiants
pubmed: 31068676
doi: 10.1038/s41418-019-0343-4
pii: 10.1038/s41418-019-0343-4
pmc: PMC7206024
doi:
Substances chimiques
Antineoplastic Agents
0
HSP110 Heat-Shock Proteins
0
HSPH1 protein, human
0
STAT3 Transcription Factor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
117-129Références
Factsheet of WHO 2012 on cancer available here: http://www.cancerresearchuk.org/sites/default/files/cs_report_world.pdf
Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. New Engl J Med. 2015;372:2509–20.
pubmed: 26028255
Chung KY, Gore I, Fong L, Venook A, Beck SB, Dorazio P, et al. Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. J Clin Oncol. 2010;28:3485–90.
pubmed: 20498386
Champiat S, Dercle L, Ammari S, Massard C, Hollebecque A, Postel-Vinay S, et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res. 2017;23:1920–8.
pubmed: 27827313
Berthenet K, Boudesco C, Collura A, Svrcek M, Richaud S, Hammann A, et al. Extracellular HSP110 skews macrophage polarization in colorectal cancer. Oncoimmunology. 2016;5:e1170264.
pubmed: 27622020
pmcid: 5006898
Berthenet K, Bokhari A, Lagrange A, Marcion G, Boudesco C, Causse S, et al. HSP110 promotes colorectal cancer growth through STAT3 activation. Oncogene. 2017;36:2328–36.
pubmed: 27819670
Guttmann DM, Koumenis C. The heat shock proteins as targets for radiosensitization and chemosensitization in cancer. Cancer Biol Ther. 2011;12:1023–31.
pubmed: 22236878
pmcid: 3335937
Calderwood SK, Khaleque MA, Sawyer DB, Ciocca DR. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci. 2006;31:164–72.
pubmed: 16483782
Schmitt E, Maingret L, Puig PE, Rerole AL, Ghiringhelli F, Hammann A, et al. Heat shock protein 70 neutralization exerts potent antitumor effects in animal models of colon cancer and melanoma. Cancer Res. 2006;66:4191–7.
pubmed: 16618741
Bonniaud P, Burgy O, Garrido C. Heat shock protein-90 toward theranostics: a breath of fresh air in idiopathic pulmonary fibrosis. Eur Respir J. 2018;51:1702612.
pubmed: 29437951
Collura A, Lagrange A, Svrcek M, Marisa L, Buhard O, Guilloux A, et al. Patients with colorectal tumors with microsatellite instability and large deletions in HSP110 T17 have improved response to 5-fluorouracil-based chemotherapy. Gastroenterology. 2014;146:401–11 e401.
pubmed: 24512910
Rampelt H, Kirstein-Miles J, Nillegoda NB, Chi K, Scholz SR, Morimoto RI, et al. Metazoan Hsp70 machines use Hsp110 to power protein disaggregation. EMBO J. 2012;31:4221–35.
pubmed: 22990239
pmcid: 3492728
Mattoo RU, Sharma SK, Priya S, Finka A, Goloubinoff P. Hsp110 is a bona fide chaperone using ATP to unfold stable misfolded polypeptides and reciprocally collaborate with Hsp70 to solubilize protein aggregates. J Biol Chem. 2013;288:21399–411.
pubmed: 23737532
pmcid: 3774407
Slaby O, Sobkova K, Svoboda M, Garajova I, Fabian P, Hrstka R, et al. Significant overexpression of Hsp110 gene during colorectal cancer progression. Oncol Rep. 2009;21:1235–41.
pubmed: 19360299
Zappasodi R, Ruggiero G, Guarnotta C, Tortoreto M, Tringali C, Cavane A, et al. HSPH1 inhibition downregulates Bcl-6 and c-Myc and hampers the growth of human aggressive B-cell non-Hodgkin lymphoma. Blood. 2015;125:1768–71.
pubmed: 25573990
Hwang TS, Han HS, Choi HK, Lee YJ, Kim YJ, Han MY, et al. Differential, stage-dependent expression of Hsp70, Hsp110 and Bcl-2 in colorectal cancer. J Gastroenterol Hepatol. 2003;18:690–700.
pubmed: 12753152
Dorard C, de Thonel A, Collura A, Marisa L, Svrcek M, Lagrange A, et al. Expression of a mutant HSP110 sensitizes colorectal cancer cells to chemotherapy and improves disease prognosis. Nat Med. 2011;17:1283–9.
pubmed: 21946539
Yu N, Kakunda M, Pham V, Lill JR, Du P, Wongchenko M, et al. HSP105 recruits protein phosphatase 2A to dephosphorylate beta-catenin. Mol Cell Biol. 2015;35:1390–1400.
pubmed: 25645927
pmcid: 4372692
Flaherty KM, DeLuca-Flaherty C, McKay DB. Three-dimensional structure of the ATPase fragment of a 70K heat-shock cognate protein. Nature. 1990;346:623–8.
pubmed: 2143562
Liu Q, Hendrickson WA. Insights into Hsp70 chaperone activity from a crystal structure of the yeast Hsp110 Sse1. Cell. 2007;131:106–20.
pubmed: 17923091
pmcid: 2041797
Santos JS, Voisin-Chiret AS, Burzicki G, Sebaoun L, Sebban M, Lohier JF, et al. Structural characterizations of oligopyridyl foldamers, alpha-helix mimetics. J Chem Inf Model. 2012;52:429–39.
pubmed: 22196240
Raviol H, Sadlish H, Rodriguez F, Mayer MP, Bukau B. Chaperone network in the yeast cytosol: Hsp110 is revealed as an Hsp70 nucleotide exchange factor. EMBO J. 2006;25:2510–8.
pubmed: 16688211
pmcid: 1478168
Joly AL, Deepti A, Seignez A, Goloudina A, Hebrard S, Schmitt E, et al. The HSP90 inhibitor, 17AAG, protects the intestinal stem cell niche and inhibits graft versus host disease development. Oncogene. 2016;35:2948.
pubmed: 27251741
Dragovic Z, Broadley SA, Shomura Y, Bracher A, Hartl FU. Molecular chaperones of the Hsp110 family act as nucleotide exchange factors of Hsp70s. EMBO J. 2006;25:2519–28.
pubmed: 16688212
pmcid: 1478182
Raviol H, Bukau B, Mayer MP. Human and yeast Hsp110 chaperones exhibit functional differences. FEBS Lett. 2006;580:168–74.
pubmed: 16364315
Oh HJ, Easton D, Murawski M, Kaneko Y, Subjeck JR. The chaperoning activity ofhsp110. Identification of functional domains by use of targeted deletions. J Biol Chem. 1999;274:15712–8.
pubmed: 10336470
Yamagishi N, Ishihara K, Hatayama T. Hsp105alpha suppresses Hsc70 chaperone activity by inhibiting Hsc70 ATPase activity. J Biol Chem. 2004;279:41727–33.
pubmed: 15292236
Andreasson C, Fiaux J, Rampelt H, Mayer MP, Bukau B. Hsp110 is a nucleotide-activated exchange factor for Hsp70. J Biol Chem. 2008;283:8877–84.
pubmed: 18218635
Buhard O, Lagrange A, Guilloux A, Colas C, Chouchene M, Wanherdrick K, et al. HSP110 T17 simplifies and improves the microsatellite instability testing in patients with colorectal cancer. J Med Genet. 2016;53:377–84.
pubmed: 26831756
Kimura A, Ogata K, Altan B, Yokobori T, Ide M, Mochiki E, et al. Nuclear heat shock protein 110 expression is associated with poor prognosis and chemotherapy resistance in gastric cancer. Oncotarget. 2016;7:18415–23.
pubmed: 26943774
pmcid: 4951298
Kimura A, Ogata K, Altan B, Yokobori T, Mochiki E, Yanai M, et al. Nuclear heat shock protein 110 expression is associated with poor prognosis and hyperthermo-chemotherapy resistance in gastric cancer patients with peritoneal metastasis. World J Gastroenterol. 2017;23:7541–50.
pubmed: 29204054
pmcid: 5698247
Scott DE, Bayly AR, Abell C, Skidmore J. Small molecules, big targets: drug discovery faces the protein-protein interaction challenge. Nat Rev Drug Discov. 2016;15:533–50.
pubmed: 27050677
Morikawa T, Baba Y, Yamauchi M, Kuchiba A, Nosho K, Shima K, et al. STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers. Clin Cancer Res. 2011;17:1452–62.
pubmed: 21310826
pmcid: 3077111
Huang W, Dong Z, Chen Y, Wang F, Wang CJ, Peng H, et al. Small-molecule inhibitors targeting the DNA-binding domain of STAT3 suppress tumor growth, metastasis and STAT3 target gene expression in vivo. Oncogene. 2016;35:802.
pubmed: 26865226
Welte T, Zhang SS, Wang T, Zhang Z, Hesslein DG, Yin Z, et al. STAT3 deletion during hematopoiesis causes Crohn’s disease-like pathogenesis and lethality: a critical role of STAT3 in innate immunity. Proc Natl Acad Sci USA. 2003;100:1879–84.
pubmed: 12571365
Mantel C, Messina-Graham S, Moh A, Cooper S, Hangoc G, Fu XY, et al. Mouse hematopoietic cell-targeted STAT3 deletion: stem/progenitor cell defects, mitochondrial dysfunction, ROS overproduction, and a rapid aging-like phenotype. Blood. 2012;120:2589–99.
pubmed: 22665934
pmcid: 3460681
Shen Y, Guo D, Weng L, Wang S, Ma Z, Yang Y, et al. Tumor-derived exosomes educate dendritic cells to promote tumor metastasis via HSP72/HSP105-TLR2/TLR4 pathway. Oncoimmunology. 2017;6:e1362527.
pubmed: 29209566
pmcid: 5706613
Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 2002;45:2615–23.
pubmed: 12036371
Martin YC. A bioavailability score. J Med Chem. 2005;48:3164–70.
pubmed: 15857122
Daina A, Zoete V. A boiled-egg to predict gastrointestinal absorption and brain penetration of small molecules. ChemMedChem. 2016;11:1117–21.
pubmed: 27218427
pmcid: 5089604
Nurizzo D, Mairs T, Guijarro M, Rey V, Meyer J, Fajardo P, et al. The ID23-1 structural biology beamline at the ESRF. J Synchrotron Radiat. 2006;13(Pt 3):227–38.
pubmed: 16645249
Kabsch W. Xds. Acta Crystallogr Sect D, Biol Crystallogr. 2010;66(Pt 2):125–32.
McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. Phaser crystallographic software. J Appl Crystallogr. 2007;40(Pt 4):658–74.
pubmed: 19461840
pmcid: 2483472
Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr Sect D, Biol Crystallogr. 2004;60(Pt 12 Pt 1):2126–32.
Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, Echols N, et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr Sect D, Biol Crystallogr. 2010;66(Pt 2):213–21.
Perrakis A, Harkiolaki M, Wilson KS, Lamzin VS. ARP/wARP and molecular replacement. Acta Crystallogr Sect D, Biol Crystallogr. 2001;57(Pt 10):1445–50.
Murshudov GN, Skubak P, Lebedev AA, Pannu NS, Steiner RA, Nicholls RA, et al. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr Sect D, Biol Crystallogr. 2011;67(Pt 4):355–67.
Chen VB, Arendall WB 3rd, Headd JJ, Keedy DA, Immormino RM, Kapral GJ, et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr Sect D, Biol Crystallogr. 2010;66(Pt 1):12–21.
DeLano WL. The PyMOL Molecular Graphics System, Version 2.0. Schrödinger, LLC. http://www.pymol.org .
Ashkenazy H, Abadi S, Martz E, Chay O, Mayrose I, Pupko T, et al. ConSurf 2016: an improved methodology to estimate and visualize evolutionary conservation in macromolecules. Nucleic Acids Res. 2016;44(W1):W344–350.
pubmed: 27166375
pmcid: 4987940